Compare Nerdwallet Inc (NRDS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Zimmer Biomet Holdings Inc — how do they compare? Nerdwallet Inc trades at $9.74 (market cap $625.17M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 27.1× Nerdwallet Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| NRDS | ZBH | |
|---|---|---|
Market Cap | $625.17M | $16.95B |
Volume | 1,321,316 | 2,505,240 |
Sector | Media | Health |
52-Week High | $15.93 | $103.98 |
52-Week Low | $7.58 | $79.58 |
Typical Hold Time | 45 Days | 89 Days |
Enterprise Value | $539.47M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.79, up 7.76% in 24 hours, with a bullish technical signal and strong profitability metrics including a 93.5% gross margin and 18.16% ROE. Recent earnings showed a Q2 2026 miss but beats in prior quarters, while revenue growth is robust, rising from $539M in 2022 to $837M in 2025. Positive cash flow trends and analyst consensus support a favorable outlook.
The stock presents a compelling value with a P/E of 10.87 and P/S of 0.81, though risks include reliance on organic search traffic and economic sensitivity. Analyst sentiment is bullish with 67% buy ratings, targeting upside potential. Continued execution on revenue growth and margin expansion are key catalysts for further gains.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
